Merus (MRUS) said Tuesday that petosemtamab in combination with pembrolizumab has received breakthrough therapy designation from the US Food and Drug Administration.
The combination therapy has been designated as the first-line treatment for adult patients with recurrent or metastatic programmed death-ligand 1 positive head and neck squamous cell carcinoma, according to updated data from an ongoing phase 1/2 trial, the company said.
Merus said that with the designation, it plans to hold discussions with the FDA about the company's goal of submitting a potential biologics license application.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。